Shots:

• The P-II study evaluate mazdutide (3.0/4.5/6.0mg) vs dulaglutide (1.5mg, SC, qw for 20wks.) or PBO in 252 patients with T2D
• The trial met its 1EPs i.e., reduction in HbA1c levels & body weight, mean change from baseline to 20wk. in HbA1c levels in mazdutide (3.0/4.5/6.0mg) were −1.41%/−1.67%/−1.54% vs −1.35% & 0.03%; HbA1c ≤7.0% @20wk. (62.8%/74.4%/78.3%) vs 69.8% & 20.0%
• Mean change from baseline to 20wk. in body weight were −7.14% for mazdutide (6.0mg) vs −2.69% & −1.38%, patients achieved HbA1c ≤7.0% & body weight reduction of ≥5% from baseline to 20wk. was 52.2% vs 14.0% & 0%, was safe & well-tolerated, and no patient withdrew due to AEs with no sev. hypoglycemia events. The safety profile was similar to prior results of mazdutide

Ref: Innovent | Image: Innovent